A promising clinical trial shows that a combination of paxalisib, pembrolizumab, and chemotherapy significantly reduces circulating tumor cells in metastatic triple-negative breast cancer.

Viking Therapeutics's obesity/diabetes candidates and strong financials position it for success. Read here for an investment ...

Australia's drug approval system is under fire, with critics in the United States claiming it is too slow to approve ...

A century ago, a Tennessee science teacher's fight to teach evolution ignited national controversy. But battles over school ...

U nder the new leadership of Marty Makary, the FDA should focus more attention on the critical role of real-world clinical ...

Generally, fighting cancer is about delivering a relentless attack on the spreading disease, but a new approach explores the ...